Syntara Limited (ASX: SNT)
Health Care · Pharmaceuticals · AU
AU$0.02
+14.29% today · -29.4% 1Y
Syntara Limited (ASX: SNT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $32.88M and employs 85 people.
Over the last twelve months the share price has lost 29.4%, trading between 0.02 and 0.04.
Tweenvest scores Syntara Limited across four factors: quality 43/100, value 53/100. Its strongest factor is value.
SNT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.88M
- Revenue (TTM)
- $4.79M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- AU$0.04
- 52-week low
- AU$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 1.96B
- Employees
- 85
- Next earnings
- —
About Syntara Limited
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
- ISIN
- AU0000312480
- Founded
- 1998
- Listed since
- Nov 28, 2023
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Navamedic ASAOB: NAVA | $33.34M | Nkr13.30 | -0.37% |
| ImmuPharma plcAIM: IMM | $33.10M | £0.04 | +21.21% |
| biote Corp.NasdaqGM: BTMD | $32.98M | $1.12 | -2.61% |
| Tianda Pharmaceuticals LimitedSEHK: 455 | $32.88M | HK$0.12 | +1.69% |
| Medical Developments International LimitedASX: MVP | $32.63M | AU$0.42 | -2.35% |
| Regent Pacific Group LimitedSEHK: 575 | $32.54M | HK$0.88 | +3.55% |
| PRISM BioLab Co.,LTDTSE: 206A | $32.45M | ¥139.00 | -4.79% |
| SoftOx Solutions ASOB: SOFTX | $32.42M | Nkr0.12 | -1.85% |
Figures last refreshed Oct 11, 2026.